22 February 2018 in Journal of Clinical Pathology
Aims: We sought to use PCR followed by high-resolution melting analysis to develop a single closed-tube screening panel to screen for Lynch syndrome. This comprises tests for microsatellite instability (MSI), MLH1 methylation promoter and BRAF mutation. Methods: For MSI testing, five mononucleotide markers (BAT25, BAT26, BCAT25, MYB, EWSR1) were developed. In addition, primers were designed to interrogate Region C of the MLH1 promoter for methylation (using bisulphite-modified DNA) and to test for mutations in codon 600 of BRAF. Two separate cohorts from Nottingham (n=99, 46 with MSI, 53 being microsatellite stable (MSS)) and Edinburgh (n=88, 45 MSI, 43 MSS) were tested. Results: All the cases (n=187) were blind tested for MSI and all were correctly characterised by our panel. The MLH1 promoter and BRAF were tested only in the Nottingham cohort. Successful blinded analysis was performed on the MLH1 promoter in 97 cases. All MSS cases showed a pattern of non-methylation while 41/44 cases with MSI showed full methylation. The three cases with MSI and a non-methylated pattern had aberrations in MSH2 and MSH6 expression. BRAF mutation was detected in 61% of MSI cases and 11% of MSS cases. Finally, 12 cases were blind screened by using the whole panel as a single test. Of these, five were identified as MSS, four as MSI/non-LS and three as MSI/possible LS. These results were concordant with the previous data. Conclusion: We describe the Nottingham Lynch Syndrome Test (N_LyST). This is a quick, simple and cheap method for screening for Lynch syndrome.
25 October 2018 in Journal of Clinical Pathology
Mutation in KRAS, BRAF and PIK3CA are commonly present in colorectal cancer (CRC). KRAS and BRAF form part of the mitogen-activated protein kinase (MAPK) signalling pathway and KRAS lies immediately upstream of BRAF. Consequently, KRAS and BRAF mutations are mutually exclusive with mutation in either one causing activation of MAPK signalling.1 PIK3CA forms part of the phosphatidylinositide‐3‐kinase PI3K signalling pathway, and several studies have shown a significant association of KRAS and PIK3CA mutation in several cancer types including CRC.1–3 At face value, there would appear to be positive co-selection of MAPK and PI3K signalling activation implying synergy between these two pathways. If this were true, then a similar positive association would be expected between mutation of BRAF and PIK3CA. To date, less consistent or no association of BRAF and PIK3CA mutation has been reported.1 3 4 However, it is well established that BRAF mutation is strongly associated with microsatellite instability (MSI) in CRC. We therefore sought to test the association between mutation of BRAF and PIK3CA …
1 August 2024 in World Journal of Oncology
High Probability of Lynch Syndrome Among Colorectal Cancer Patients Is Associated With Higher Occurrence of KRAS and PIK3CA Mutations
6 June 2025 in Research Square
In the colonic epithelium, fetal programming is induced by Yes-associated protein (YAP) signaling, which is associated with tumorigenesis and progression in colorectal cancer (CRC). While CRC was long considered a WNT driven disease, here we show that fetal programmed cells with activated YAP signaling can arise independently of WNT activation. Fetal programmed cells, in the presence of hyper- or hypo-activated WNT, have different characteristics and are associated with poor relapse. Furthermore, using various mouse models, we demonstrated the conserved characteristics of two different fetal programmed cell states with different WNT activation, which can be switched from a hyperactivated to hypoactivated WNT state based on genetic alteration, particularly Kras mutation. Taken together, these data redefine the key determinants of epithelial cell states in colorectal cancer and integrate emerging preclinical biology into a robust landscape of states observed in human and mouse.
3 November 2024 in Epigenetics
MAMuhammad Zulfikar Arief
ARAsep Muhamad Ridwanuloh
+13
Stunting is the result of chronic malnutrition due to the lack of micronutrient-based methyl donors required for epigenetic programming during the first 1000 days of life. Methylation studies using bisulfite conversion from blood DNA are invasive and may not be practical for large-scale epidemiological investigation or nutrition intervention programs. Buccal epithelial methylation may reflect early germline methylation. Therefore, buccal cells can serve as convenient sample sources to collect biomarkers associated with the risk of stunting. This study aims to describe the feasibility of nanopore adaptive sampling in detecting DNA methylation from children’s buccal DNA. We used adaptive sampling of Oxford Nanopore Technology on barcoded samples to describe differential methylation associated with malnutrition. Overall, the level of 5-methylcytosine (5mC) was lower in stunted children than in normal children. We also found differentially methylated regions at the MIR6724 and RNA45SN1 gene loci on chromosome 21, which was higher in stunted children than in normal children. We described and detected differential DNA methylation in the locus previously not known to be associated with stunting. Interestingly, this locus on chromosome 21 has been implicated in the stunted phenotype of Down syndrome.